This is the protocol for a review and there is no abstract. The objectives are as follows:
To quantify the effects of various doses of rosuvastatin on serum total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides in subjects with and without evidence of cardiovascular disease. The primary focus of the review will be on the mean per cent change of LDL-cholesterol.
To quantify the variability of the effect of various doses of rosuvastatin.
To quantify withdrawals due to adverse effects in the randomized placebo controlled trials.